Microsoft: Analysts Anticipate Q4 Earnings Per Share Of $2.29

Microsoft (NASDAQ: MSFT) will be reporting its fiscal fourth quarter financials today after markets close. Analysts have a consensus $344 12-month price target on the company, via a total of 52 analysts, with 19 analysts having strong buy ratings. 30 analysts meanwhile have buy ratings and three analysts have hold ratings. The street high sits at a $426 price target, and the lowest target sits at $252.

24 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 24 analysts is $52.39 billion; this number is flat year to date now. The highest revenue estimate is $52.9 billion, while the lowest is $51.74 billion.

Onto EBITDA estimates, there are currently only six analysts who have fourth-quarter EBITDA estimates. The mean is currently $25.1 billion, with this number having been revised downwards from $25.4 billion at the start of the year. Street high is a $25.34 billion EBITDA estimate and the lowest is $24.88 billion.

Analysts estimate that quarterly earnings per share will come in at $2.29, with this number being revised steadily down since the start of the year. Street high is $2.35, and the lowest estimate is $2.24 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Everybody Should Own Gold | George Bee – U.S. Gold Corp.

A $40M Company Created $2B in Mining Value | John-Mark Staude – Riverside Resources

The Debt Crisis Is Turning Gold Into Money | Shawn Khunkhun – Contango Silver and Gold

Recommended

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Altamira Gold Drills 134 Metres of 0.5 g/t Gold at Maria Bonita, Hole Ends in Mineralization

Related News

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM

CareRx: Canaccord Raises Price Target To $6.50 Following Financing

Earlier this week, CareRx Corp (TSX: CRRX) closed their C$21.2 million bought deal. Notably, $6.25...

Friday, February 5, 2021, 11:45:00 AM

K92 Mining Sees Analysts Reiterate Ratings Following Drill Results

Last week, K92 Mining Inc. (TSX: KNT) reported their Judd Vein System drill results, which...

Sunday, September 5, 2021, 04:50:00 PM

Trulieve: Analysts Raise Price Targets Following Q4 Results

Yesterday, Trulieve Cannabis (CSE: TRUL) announced their fourth quarter and year-end financial for 2020. The...

Saturday, March 27, 2021, 02:45:00 PM

Pure Gold: Canaccord Suspends Rating After Operational Struggles

On Friday, Pure Gold Mining (TSXV: PGM) announced a number of updates for its investors....

Wednesday, April 27, 2022, 12:19:00 PM